In a report released on February 7, Roger Samuel from Jefferies maintained a Hold rating on PEXA Group Limited (PXA – Research Report), with a price target of A$13.00. The company’s shares ...
South Korean biotech Sillajen was hit hard last week when its oncolytic virus therapy Pexa-Vec failed a phase 3 trial, but the company reckons it doesn’t spell the end of the programme.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback